

Prevention & Treatment of Hepatitis and Chronic Liver Disease

Las Vegas, NV March 31 – April 1, 2023

Conference Location	Las Vegas Flamingo Hotel 3555 Las Vegas Blvd, South Las Vegas, NV 89109	(702) 733-3111 https://www.caesars.com/flamingo-las-vegas
----------------------------	--	---

Guest Rooms at the Conference	A special nightly guest room rate of \$194 single or double. (Upgraded King room - <i>Including resort fees</i>) is available on Friday and Saturday evenings and only \$95 on Thursday. Plus, participants will earn \$10 per night food and beverage credit to be used at hotel outlets. Please go to: https://book.passkey.com/go/SFCLD3 to secure your room. But hurry – these rates are only available until March 9, 2023
--------------------------------------	---

Driving Directions	The hotel is located mid-Strip on Las Vegas Boulevard, one-half block South of Flamingo Road.
---------------------------	---

Seminar Agenda and Syllabus Information	Registration begins at Friday 12:00 noon. in the Virginia City Rooms – 3 rd floor, Spa Tower The Hepatitis and Chronic Liver Disease seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the App will be provided. Wi-Fi will be provided.
--	--

Pre-Program Activities	Pre-Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min Pre-Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
FRI MARCH 31	
12:00 pm	<i>Registration, Refreshments and View Exhibits</i>
1:00 pm	Opening Comments and Pre-Test
1:20 pm	Review of Viral Hepatitis –HCV <ul style="list-style-type: none"> Highlight of Pre-Lecture 1 Screening and Treatment of HCV Clinical Cases and Discussion
2:00 pm	Hepatitis B: Epidemiology, Natural History and Testing <ul style="list-style-type: none"> The epidemiology of the Hepatitis B infection Efficacies and opportunities in HBV testing and vaccination Anti-viral therapies of HBV The growing relationship between HBV and HDV
2:40pm	Delta Hepatitis and Hepatitis E Update <ul style="list-style-type: none"> Worldwide perspective and promising research studies Real world outcome studies on HDV and HEV
3:00 pm	Afternoon break
3:15 pm	End Stage Liver Disease: Recap and Clinical Cases <ul style="list-style-type: none"> A review of Pre-course lecture on end-stage liver disease Clinical cases to illustrate HE and Thrombocytopenia The liver transplant process and its challenges

Friday (con't) 3:45 pm	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> The aggressive growth of liver cancer and disease progression in the US and worldwide Screening Approaches: diagnostic serum assays and imaging tests Treatment and management options: Ablation, TACE and Surgery
4:15 pm	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> A case-based approach to HCC treatment Current FDA-Approved Therapies New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC
5:00 pm	<i>Product Theater # 1 Cocktail Reception and View exhibits</i>
SAT April 1 7:30 am	Breakfast Session and View Exhibits
8:15 am	Cholestatic Liver Disease: Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) <ul style="list-style-type: none"> Epidemiology of PSC and Ursodiol and Antibiotic Treatments Predicting outcomes and Improving Survival in PSC patients Causes and Markers of PBC Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
9:00 am	Alcohol Associated Liver Disease <ul style="list-style-type: none"> The growing prevalence of alcohol over-consumption and its impact on liver health How the COVID pandemic changed America's drinking habits Warning signs and intervention in alcohol-associated hepatitis
9:30 am	Fluid Management, Ascites and Hepatorenal Syndrome <ul style="list-style-type: none"> The diagnosis and treatment of ascites How cirrhosis can lead to portal hypertension, ascites, kidney disease and hepatorenal syndrome New and emerging treatment approaches for of HRS
10:00 Am	<i>Break & View Exhibits</i>
10:15 am	NAFLD and NASH <ul style="list-style-type: none"> Epidemiology, Demographics and Diagnosis Scoring, Staging and Management of Fatty Liver Disease Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
11:00am	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> Current therapies for NASH including Updates from AASLD and EASL Lifestyle changes as a therapy Therapies in clinical development for NASH
11:50 am	Closing Comments, Post-test, and Wrap-Up Program adjourns at 12:00 noon

Attendee Cancellation, Substitution, Refund: The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Attendance Policies

Recording and Photography; The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations, and other purposes.

Guest Attendance: All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)[™]**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for **12.0 continuing education** credits through University of Louisville Hospital, provider number 4-0068-12-22-1264. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)[™] organizations accredited by ACCME.

Your Seminar Faculty**SAMMY SAAB, MD, MPH**

Sammy Saab is a Professor in the Departments of Internal Medicine and Surgery at the David Geffen School of Medicine. He is also Head of Outcomes Research in Hepatology at the Pflieger Liver Institute. Dr. Saab received his BS, MD, and MPH from UCLA. He completed his residency in internal medicine at University of California at San Diego Medical Center and a fellowship in gastroenterology/hepatology at UCLA Center for Health Sciences. Dr. Saab is board certified in internal medicine, gastroenterology, and transplant hepatology.

He has received honorary fellowships from the American Gastroenterology Association (AGAF), American College of Gastroenterology (FACG) and the American Association for the Study of Liver Diseases (FAASLD).

**MICHAEL VOLK, MD, MSc**

Dr. Volk is the Chief of Gastroenterology and Hepatology, and Medical Director of Liver Transplantation at Loma Linda University. He is triple board certified in Transplant Hepatology, Gastroenterology, and Internal Medicine, and has been frequently selected by Best Doctors as among the top Hepatologists in the country.

He is a former Robert Wood Johnson Clinical Scholar, with a longstanding funded research program that focuses on management of cirrhosis and organ allocation for liver transplantation. He has published >130 research articles, reviews, and book chapters, and serves on multiple national committees.

**CORRIE BERK, DNP, MBA**

Corrie Berk, DNP, MBA, APRN is Associate Professor and Director of the Family Nurse Practitioner and Adult-Gerontology Nurse Practitioner programs at Loma Linda University School of Nursing. She practices clinically at Loma Linda University Health's Las Vegas and Palm Springs campuses of the Transplant Institute.

Dr. Berk is Chair of the Hepatology Associates Committee for the American Association for the Study of Liver Diseases (AASLD) and was the Hepatology Associates Course Director for The Liver Meeting 2022. She also serves on the Advanced Transplant Provider (ATP) committee for the American Society of Transplant Surgeons (ASTS) and is a faculty advisor and speaker for Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), and the treasurer of the Las Vegas Liver Foundation.